Back to search results

Phase 2 Study of Radioembolization vs. External Radiation for Liver Cancer

This study is comparing two radiation treatments for hepatocellular carcinoma (a type of liver cancer): Transarterial Radioembolization (TARE) and Stereotactic Body Radiation Therapy (SBRT). TARE involves delivering Yttrium-90 directly to the tumor through an artery. SBRT uses external radiation given in a few sessions. The study aims to see which treatment leads to fewer re-treatments of the tumor over 12 months. You may be able to join if you are 18 or older, have up to 3 liver cancer lesions, and meet certain health criteria. The study is currently unclear on its recruitment status and plans to enroll 146 participants.

Study design
This is a single-site, randomized Phase 2 study comparing two radiation treatments. It plans to enroll 146 participants.
What's involved
You would undergo either Transarterial Radioembolization (TARE) or Stereotactic Body Radiation Therapy (SBRT). The study will follow you for 12 months after treatment ends.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 12 months after the end of their treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07530172

Radioembolization Versus External Radiation Therapy

Recruiting
PHASE2Ages 18+InterventionalTreatment
Henry Ford Health System
~146 participants
Updated 2026-04-15 on ClinicalTrials.gov
What's tested:Transarterial RadioembolizationStereotactic Body Radiation Therapy (SBRT)

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Rate of re-treatment over 12 months
Measured over From enrollment to 12 months following the end of treatment

Conditions

Heptocellular Cancer

Explore related trials

Hepatocellular Carcinoma

NCT07530172

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Henry Ford Health System

    Detroit, Michiganstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Reena Salgia, MD · PRINCIPAL_INVESTIGATOR · Henry Ford Health System

Who to contact

Marissa Gilbert
[email protected]
313-556-8422
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Ability to provide written informed consent and HIPAA authorization
Stated willingness to comply with all study procedures and availability for the duration of the study
Male or female, aged ≥ 18 years at time of informed consent
No more than 3 lesions of HCC evaluated to be eligible for TARE or SBRT at multidisciplinary tumor board
Childs-Pugh score ≤ 8
ECOG performance status ≤2
Adequate organ function defined as:
serum bilirubin \< 4.0 mg/dL ,
albumin \> 2 g/dL

Exclusion

Any prior SBRT or radioembolization to the target tumor
Macrovascular invasion
Planned or recommended systemic therapy as consolidation
Pregnancy or lactation: Women of childbearing potential must have a negative pregnancy test within 14 days of protocol registration.
Known severe allergic reaction (anaphylaxis) to iodinated contrast Coagulopathy that the provider deems would be unsafe for transarterial therapy

What this trial measures

  • Rate of re-treatment over 12 monthsFrom enrollment to 12 months following the end of treatment

    Rate of re-treatment of the index lesion over 12 months